Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06767462 · ClinicalTrials.gov registry record
An Ophthalmic Safety Study in Patients With Breast Cancer
A clinical trial of Ophthalmic Safety in Patients With Breast Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- 160
- Enrollment target
- 20
- Study locations
NCT06767462 is a study of Ophthalmic Safety in Patients With Breast Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 160 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT06767462, a study of Ophthalmic Safety in Patients With Breast Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess ophthalmic health in parallel cohorts of patients with breast cancer
Conditions Studied
Study Locations (20)
Other
- Research Site - Buenos Aires
- Research Site - Buenos Aires
- Research Site - CABA
- Research Site - Córdoba
- Research Site - San Miguel de Tucumán
- Research Site - San Miguel de Tucumán
- Research Site - Edegem
- Research Site - Leuven
California
- Research Site - La Jolla
- Research Site - Palo Alto
- Research Site - San Diego
Pennsylvania
- Research Site - Clairton
- Research Site - Pittsburgh
Iowa
- Research Site - Iowa City
New York
- Research Site - New York
North Carolina
- Research Site - Winston-Salem
Ohio
- Research Site - Cleveland
South Dakota
- Research Site - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-03-04 |
| Est. Completion | 2027-07-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06767462
The ClinicalTrials.gov registry entry for NCT06767462 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ophthalmic Safety in Patients With Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06767462 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06767462 about?
NCT06767462 is a clinical study titled "An Ophthalmic Safety Study in Patients With Breast Cancer". To assess ophthalmic health in parallel cohorts of patients with breast cancer
What is the current status of trial NCT06767462?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2025-03-04. Estimated completion is 2027-07-06.
What conditions does trial NCT06767462 study?
This clinical trial studies the following conditions: Ophthalmic Safety in Patients With Breast Cancer.
Who is sponsoring clinical trial NCT06767462?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06767462 being conducted?
This trial has 20 study locations across California, Iowa, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.